It’s getting harder to get a preferred brand name for a new drug or biologic through the Food & Drug Administration. About two in five proprietary names proposed by drug sponsors are now turned down by FDA prior to the approval of a new product.
That’s a jump from FDA’s historical rejection rates. At the beginning of the decade, the agency tossed out about 33%...